*Press Release Courtesy of "Crystal Research Associates":http://www.crystalra.com*
NEW YORK, NY (February 22, 2006)…..Crystal Research Associates, LLC announced today that it has issued an Executive Informational Overview® (EIO®) on Worcester, Massachusetts-based Advanced Cell Technology, Inc. (OTCBB: ACTC.OB). The full 60-page report can be found at "www.crystalra.com":http://www.crystalra.com, or on Advanced Cell Technology's web site by clicking "here.":/filedownload/76
Advanced Cell Technology, Inc. ("Advanced Cell” or "the Company”) is a biotechnology company applying human embryonic stem (ES) cell technology to the emerging field of regenerative medicine. Regenerative medicine refers to "cell therapy”, or treatments that are founded on the concept of producing new cells to replace malfunctioning or damaged cells as a vehicle to treat disease and injury.
Advanced Cell's technologies are currently in the pre-clinical research stage, with the goal of commercializing their use in treating a wide array of chronic degenerative diseases, and in regenerative repair of acute injuries and conditions such as trauma, infarction, and burns. Advanced Cell believes that these reprogramming technologies could produce cells that would maximize the potential for effective use as transplants for replacing diseased or destroyed cells in human patients. These technologies may also avoid reliance on more limited approaches that involve the use of cell lines that may not be histocompatible with the patient, or therapies based upon the use of adult stem cells.
Advanced Cell's research is focused within three core areas: (1) Cellular Reprogramming, which enables the transformation of a patient's own cells into ES cells, which can then be differentiated into specific cells for therapies for a variety of diseases, (2) a Reduced Complexity Library (RCL), enabling production of histocompatible stem cell lines for "off-the-shelf” deployment to treat acute disease in time-critical situations, which are not amenable to reprogramming technologies, and (3) Stem Cell Differentiation, which is designed to control the differentiation and re-differentiation of stem cells into specific cell types, such as hematopoetic, myocardial, skin, retinal, and neuronal cells for therapeutic applications.
To date, the Company has announced its focus on three product programs to develop therapeutics for indications in the eye, skin, and blood. Advanced Cell is headquartered in Worcester, Massachusetts, where the Company houses a Good Manufacturing Practices (GMP)-capable facility to manufacture product for preclinical and clinical testing. The Company also has a facility in Alameda, California, which includes 10,000 square feet of GMP-capable production facilities.
Jeffrey J. Kraws/Karen B. Goldfarb
Crystal Research Associates, LLC
P: (609) 306-2274/F: (609) 395-9339